Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status
- Resource Type
- Authors
- Michael J. Lind; Philip J. Drew; Victoria C. Hodgkinson; Lynn Cawkwell; Gina L. Eagle
- Source
- Cancer letters. 294(1)
- Subject
- Sample selection
Proteomics
Cancer Research
Spectrometry, Mass, Electrospray Ionization
Antibody microarray
Breast Neoplasms
Computational biology
Breast cancer
Stable isotope labeling by amino acids in cell culture
Biomarkers, Tumor
Medicine
Humans
RNA, Messenger
Peptide-mass fingerprint
business.industry
Genome, Human
medicine.disease
Molecular biology
Neoplasm Proteins
Alternative Splicing
Oncology
Drug Resistance, Neoplasm
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Mutation
Electrophoresis, Polyacrylamide Gel
Female
DNA microarray
business
Protein Processing, Post-Translational
Chemotherapy resistance
- Language
- ISSN
- 1872-7980
This review describes and discusses the advantages and limitations of proteomic approaches in the identification of biomarkers associated with chemotherapy resistance. Both gel-based (two-dimensional polyacrylamide gel electrophoresis) and gel-free (shotgun and quantitative) mass spectrometry approaches are discussed. Non-mass spectrometry approaches including antibody microarray platforms are described as complementary proteomic strategies. Methods for technical confirmation and clinical validation of putative biomarkers are presented. Use of this proteomic toolbox in the quest for biomarkers of chemotherapy resistance in breast cancer is reviewed. Technical aspects of sample selection, acquisition, storage and analysis are discussed and putative biomarkers identified through proteomic approaches are presented.